NCT04977167 2024-10-10
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
HitGen Inc.
Phase 1 Unknown
Clinical Trials
1,166 trialsNCT05452668 2024-08-21
Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients
Children's Cancer Hospital Egypt 57357
Phase NA Unknown
NCT05606380 2024-04-16
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05995873 2024-03-26
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
MindLight, LLC
Phase NA Unknown
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT06293586 2024-03-05
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Cairo University
Phase NA Unknown
NCT02682641 2024-02-26
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Unknown
NCT03576378 2024-02-26
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Unknown
NCT06277011 2024-02-26
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
NCT06170216 2024-02-23
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
Fudan University
Unknown
NCT06206902 2024-02-23
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Unknown
NCT05865678 2024-02-21
SKETCh
The Christie NHS Foundation Trust
Unknown
NCT03650933 2024-02-20
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Nanjing Yoko Biomedical Co., Ltd.
Phase 3 Unknown
NCT06148220 2024-02-16
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
Huashan Hospital
Phase NA Unknown
NCT05284825 2024-02-15
A Phase II Trial of Intermediate Radiation Dose For Lymphoma
Sunnybrook Health Sciences Centre
Phase NA Unknown
NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
NCT05875428 2024-02-08
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04582487 2024-02-07
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT04731974 2024-02-07
Acute Concussion and Melatonin
Children's National Research Institute
Phase 2 Unknown
NCT05234684 2024-02-07
BELIEVE-01
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05358379 2024-02-07
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT03789097 2024-01-30
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT05422521 2024-01-30
CART-Omic
Centre Hospitalier Universitaire de Nice
Phase NA Unknown
NCT05150405 2024-01-23
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05450146 2024-01-23
Trial-based Effectiveness and Cost-effectiveness of the Partner in Balance Intervention
Maastricht University
Phase NA Unknown
NCT06211881 2024-01-18
Chi-GVM Regimen for the Treatment of R/R PTCL
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT06202885 2024-01-12
CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy
Seoul St. Mary's Hospital
Unknown
NCT05078840 2024-01-09
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
Grupo Argentino de Tratamiento de la Leucemia Aguda
Unknown
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT05420493 2024-01-05
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT05460767 2023-12-29
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT01827605 2023-12-14
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Fondazione Italiana Linfomi - ETS
Phase 3 Unknown
NCT03617666 2023-12-12
AVENuE
University College, London
Phase 2 Unknown
NCT04407741 2023-12-12
Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05728801 2023-12-12
Decoding the Cognitive Trajectory of Hong Kong SuperAgers: a Longitudinal Follow-up Study
Chinese University of Hong Kong
Unknown
NCT05846672 2023-12-12
Turkish Cultural Adaptation, Validity and Reliability of the "Gait Outcomes Assessment List"
Istanbul University - Cerrahpasa
Unknown
NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown
NCT06160362 2023-12-07
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
Phase NA Unknown
NCT04599556 2023-12-06
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Zhejiang University
Phase 1 Unknown
NCT05113069 2023-12-06
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT03341520 2023-11-30
GAZAI
Heidelberg University
Phase 2 Unknown
NCT03064269 2023-11-29
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT05025150 2023-11-28
Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial
Sutter Health
Unknown
NCT05803395 2023-11-28
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT04089215 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown